• 12848 Citations
  • 39 h-Index
1973 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

2016

Lapatinib-related rash and breast cancer outcome in the ALTTO phase III randomized trial

Sonnenblick, A., De Azambuja, E., Agbor-Tarh, D., Bradbury, I., Campbell, C., Huang, Y., Dueck, A. C., Pritchard, K. I., Wolff, A. C., Jackisch, C., Lang, I., Untch, M., Smith, I., Boyle, F., Xu, B., Gomez, H., Perez, E. A., Piccart, M. & Azim, H. A., 2016, In : Journal of the National Cancer Institute. 108, 8, djw037.

Research output: Article

14 Citations (Scopus)

Low-dose oral cyclophosphamide and methotrexate maintenance for hormone receptor-negative early breast cancer: International Breast Cancer Study Group Trial 22-00

Colleoni, M., Gray, K. P., Gelber, S., Láng, I., Thürlimann, B., Gianni, L., Abdi, E. A., Gomez, H. L., Linderholm, B. K., Puglisi, F., Tondini, C., Kralidis, E., Eniu, A., Cagossi, K., Rauch, D., Chirgwin, J., Gelber, R. D., Regan, M. M., Coates, A. S., Price, K. N. & 2 others, Viale, G. & Goldhirsch, A., okt. 1 2016, In : Journal of Clinical Oncology. 34, 28, p. 3400-3408 9 p.

Research output: Article

38 Citations (Scopus)

Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu- positive advanced breast cancer: Results of the CECOG LaVie trial

Thallinger, C., Lang, I., Kuhar, C. G., Bartsch, R., Singer, C. F., Petruzelka, L., Melichar, B., Knittelfelder, R., Brodowicz, T. & Zielinski, C., febr. 18 2016, In : BMC cancer. 16, 1, 121.

Research output: Article

4 Citations (Scopus)

Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer

Zielinski, C., Lang, I., Beslija, S., Kahan, Z., Inbar, M. J., Stemmer, S. M., Anghel, R., Vrbanec, D., Messinger, D. & Brodowicz, T., jan. 19 2016, In : British journal of cancer. 114, 2, p. 163-170 8 p.

Research output: Article

11 Citations (Scopus)

Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: Primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)

Jerusalem, G., Mariani, G., Ciruelos, E. M., Martin, M., Tjan-Heijnen, V. C. G., Neven, P., Gavila, J. G., Michelotti, A., Montemurro, F., Generali, D., Simoncini, E., Lang, I., Mardiak, J., Naume, B., Camozzi, M., Lorizzo, K., Bianchetti, S. & Conte, P., szept. 1 2016, In : Annals of Oncology. 27, 9, p. 1719-1725 7 p.

Research output: Article

24 Citations (Scopus)

Treatment adherence and its impact on Disease-Free survival in the breast international group 1-98 trial of tamoxifen and letrozole, alone and in sequence

Chirgwin, J. H., Giobbie-Hurder, A., Coates, A. S., Price, K. N., Ejlertsen, B., Debled, M., Gelber, R. D., Goldhirsch, A., Smith, I., Rabaglio, M., Forbes, J. F., Neven, P., Láng, I., Colleoni, M. & Thürlimann, B., júl. 20 2016, In : Journal of Clinical Oncology. 34, 21, p. 2452-2459 8 p.

Research output: Article

72 Citations (Scopus)

Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00

Pruneri, G., Gray, K. P., Vingiani, A., Viale, G., Curigliano, G., Criscitiello, C., Láng, I., Ruhstaller, T., Gianni, L., Goldhirsch, A., Kammler, R., Price, K. N., Cancello, G., Munzone, E., Gelber, R. D., Regan, M. M. & Colleoni, M., júl. 1 2016, In : Breast Cancer Research and Treatment. 158, 2, p. 323-331 9 p.

Research output: Article

54 Citations (Scopus)

Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): The SOFT-EST substudy

Bellet, M., Gray, K. P., Francis, P. A., Láng, I., Ciruelos, E., Lluch, A., Climent, M. A., Catalán, G., Avella, A., Bohn, U., González-Martin, A., Ferrer, R., Catalán, R., Azaro, A., Rajasekaran, A., Morales, J., Vázquez, J., Fleming, G. F., Price, K. N. & Regan, M. M., máj. 10 2016, In : Journal of Clinical Oncology. 34, 14, p. 1584-1593 10 p.

Research output: Article

52 Citations (Scopus)
2017

Adjuvant pertuzumab and trastuzumab in early her2-positive breast cancer

Von Minckwitz, G., Procter, M., De Azambuja, E., Zardavas, D., Benyunes, M., Viale, G., Suter, T., Arahmani, A., Rouchet, N., Clark, E., Knott, A., Lang, I., Levy, C., Yardley, D. A., Bines, J., Gelber, R. D., Piccart, M. & Baselga, J., júl. 13 2017, In : New England Journal of Medicine. 377, 2, p. 122-131 10 p.

Research output: Article

381 Citations (Scopus)

Cholesterol, cholesterol-lowering medication use, and breast cancer outcome in the BIG 1-98 study

Borgquist, S., Giobbie-Hurder, A., Ahern, T. P., Garber, J. E., Colleoni, M., Láng, I., Debled, M., Ejlertsen, B., Von Moos, R., Smith, I., Coates, A. S., Goldhirsch, A., Rabaglio, M., Price, K. N., Gelber, R. D., Regan, M. M. & Thürlimann, B., ápr. 10 2017, In : Journal of Clinical Oncology. 35, 11, p. 1179-1188 10 p.

Research output: Article

36 Citations (Scopus)

memo: Spectacular developments during the last decade from the Section Editors’ point of view

Hofer, S., Gunsilius, E., Láng, I. & Moiseyenko, V., febr. 1 2017, In : Memo - Magazine of European Medical Oncology. 10, 1, p. 4-7 4 p.

Research output: Editorial

Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial

On behalf of CALOR trial investigators, febr. 1 2017, In : Annals of Surgical Oncology. 24, 2, p. 398-406 9 p.

Research output: Article

12 Citations (Scopus)

predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab

Duchnowska, R., Sperinde, J., Czartoryska-Arlukowicz, B., Myśliwiec, P., Winslow, J., Radecka, B., Petropoulos, C., Demlova, R., Orlikowska, M., Kowalczyk, A., Láng, I., Ziółkowska, B., Debska-Szmich, S., Merdalska, M., Grela-Wojewoda, A., Zawrocki, A., Biernat, W., Huang, W. & Jassem, J., jan. 1 2017, In : Oncotarget. 8, 61, p. 104149-104159 11 p.

Research output: Article

7 Citations (Scopus)
2018

Efficacy of chemotherapy for ER-negative and ER-positive isolated locoregional recurrence of breast cancer: Final analysis of the CALOR trial

Wapnir, I. L., Price, K. N., Anderson, S. J., Robidoux, A., Martín, M., Nortier, J. W. R., Paterson, A. H. G., Rimawi, M. F., Láng, I., Baena-Cañada, J. M., Thürlimann, B., Mamounas, E. P., Geyer, C. E., Gelber, S., Coates, A. S., Gelber, R. D., Rastogi, P., Regan, M. M., Wolmark, N. & Aebi, S., ápr. 10 2018, In : Journal of Clinical Oncology. 36, 11, p. 1073-1079 7 p.

Research output: Article

29 Citations (Scopus)
2 Citations (Scopus)

Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00

Munzone, E., Gray, K. P., Fumagalli, C., Guerini-Rocco, E., Láng, I., Ruhstaller, T., Gianni, L., Kammler, R., Viale, G., Di Leo, A., Coates, A. S., Gelber, R. D., Regan, M. M., Goldhirsch, A., Barberis, M. & Colleoni, M., júl. 1 2018, In : Breast Cancer Research and Treatment. 170, 2, p. 351-360 10 p.

Research output: Article

2 Citations (Scopus)

Predictive Value of Early Skin Rash in Cetuximab-Based Therapy of Advanced Biliary Tract Cancer

Rubovszky, G., Budai, B., Ganofszky, E., Horváth, Z., Juhos, É., Madaras, B., Nagy, T., Szabó, E., Pintér, T., Tóth, E., Nagy, P., Láng, I. & Hitre, E., ápr. 1 2018, In : Pathology and Oncology Research. 24, 2, p. 237-244 8 p.

Research output: Article

4 Citations (Scopus)
2019

Adjuvant Anti-HER2 Therapy, treatment-related amenorrhea, and survival in premenopausal HER2-positive early breast cancer patients

Lambertini, M., Campbell, C., Bines, J., Korde, L. A., Izquierdo, M., Fumagalli, D., Del Mastro, L., Ignatiadis, M., Pritchard, K., Wolff, A. C., Jackisch, C., Lang, I., Untch, M., Smith, I., Boyle, F., Xu, B., Barrios, C. H., Baselga, J., Moreno-Aspitia, A., Piccart, M. & 2 others, Gelber, R. D. & De Azambuja, E., jan. 1 2019, In : Journal of the National Cancer Institute. 111, 1, djy094.

Research output: Article

18 Citations (Scopus)

Survival outcomes of the NeoALTTO study (BIG 1–06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer

Huober, J., Holmes, E., Baselga, J., de Azambuja, E., Untch, M., Fumagalli, D., Sarp, S., Lang, I., Smith, I., Boyle, F., Xu, B., Lecocq, C., Wildiers, H., Jouannaud, C., Hackman, J., Dasappa, L., Ciruelos, E., Toral Pena, J. C., Adamchuk, H., Hickish, T. & 5 others, de la Pena, L., Jackisch, C., Gelber, R. D., Piccart-Gebhart, M. & Di Cosimo, S., szept. 2019, In : European Journal of Cancer. 118, p. 169-177 9 p.

Research output: Article

3 Citations (Scopus)
2020

Absolute improvements in freedom from distant recurrence to tailor adjuvant endocrine therapies for premenopausal women: Results from TExT and Soft

Pagani, O., Francis, P. A., Fleming, G. F., Walley, B. A., Viale, G., Colleoni, M., Láng, I., Gómez, H. L., Tondini, C., Pinotti, G., Di Leo, A., Coates, A. S., Goldhirsch, A., Gelber, R. D. & Regan, M. M., ápr. 20 2020, In : Journal of Clinical Oncology. 38, 12, p. 1293-1303 11 p.

Research output: Article

Open Access
7 Citations (Scopus)

Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial

Eiger, D., Pondé, N. F., Agbor-Tarh, D., Moreno-Aspitia, A., Piccart, M., Hilbers, F. S., Werner, O., Chumsri, S., Dueck, A., Kroep, J. R., Gomez, H., Láng, I., Rodeheffer, R. J., Ewer, M. S., Suter, T. & de Azambuja, E., máj. 12 2020, In : British journal of cancer. 122, 10, p. 1453-1460 8 p.

Research output: Article